The Smith family moved from Scotland to Caledon, Ontario and started buying up swathes of land. The family were prominent in ...
Jan. 14, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, today ...
Jan. 14, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Company" or "Quoin"), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases ...
(RTTNews) - Quoin Pharmaceuticals, Ltd. (QNRX) Tuesday announced positive interim clinical data from its ongoing Investigator Pediatric Netherton Syndrome clinical study using QRX003. The data ...
Jan. 14, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company ...
Jan. 14, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan ...
ASHBURN, Va. - Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX), a clinical-stage specialty pharmaceutical company with a market capitalization of $2.89 million, announced positive interim clinical data ...
Quoin Pharmaceuticals (QNRX) announces interim clinical data from its ongoing Investigator Pediatric Netherton Syndrome clinical study. The Investigator Pediatric Study continues to demonstrate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback